Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Metastatic Breast Cancer – Part 2

In this second interactive patient case video from BREAST CANCER CONNECT, Prof. Valentina Guarneri presents a patient with ER+/HER2- metastatic breast cancer, focusing on tumour characteristics, treatment strategies, and the management of adverse events.

As you journey through the entire diagnostic and treatment process, you'll interact and engage with valuable information, challenging questions and clickable resources along the way.

Catch up on the first case study to hear Dr Elisa Agostinetto present a patient with ER+/HER2- de novo metastatic breast cancer.

Clinical Takeaways

• Assessing tumour characteristics, including prevalent mutations like ESR1 and PIK3CA, can significantly influence and guide treatment choices in patients with ER+/HER2- metastatic breast cancer

• Liquid biopsy, specifically blood-based ctDNA analysis, is the preferred method for detecting ESR1 mutations due to its heightened sensitivity and the avoidance of repeat biopsies at metastatic sites

• Elacestrant, as the first FDA-approved oral SERD (January 2023), offers a promising choice for select patients with ER+/HER2-  metastatic breast cancer harbouring an ESR1 mutation

• Oral SERDs are being studied as a monotherapy and in combination with targeted therapies (i.e. CDK4/6, PI3K and AKT inhibitors), offering promising prospects for their integration into clinical practice